Multiple Sclerosis Drugs - Portugal

Portugal

The Multiple Sclerosis Drugs market is expected to witness significant growth in Portugal.
According to projections, the market's revenue is estimated to reach US$46.08m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2028) of 1.42%, leading to a market volume of US$48.75m by 2028.
In comparison to other countries, United States is projected to generate the highest revenue, amounting to US$12,360.00m in 2024.
Portugal's multiple sclerosis drug market is experiencing significant growth, driven by increased government funding and a growing patient population.

Key regions: South Korea, Brazil, Australia, China, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Portugal has seen significant growth in recent years.

Customer preferences: Patients in Portugal prefer disease-modifying therapies (DMTs) that are effective in reducing the frequency and severity of relapses. They also prefer oral medications over injectables due to convenience and ease of use.

Trends in the market: The market has experienced a shift towards newer oral medications, such as fingolimod and teriflunomide, which have been proven to be effective in reducing relapse rates. The market has also seen an increase in the use of biosimilars, which offer a more affordable alternative to expensive biologic drugs.

Local special circumstances: The Portuguese government has implemented policies to reduce healthcare spending, which has led to a greater emphasis on cost-effective treatments. This has led to increased competition among drug manufacturers, with companies offering discounts and rebates to gain market share.

Underlying macroeconomic factors: The Portuguese economy has been recovering from the financial crisis of the late 2000s, which has led to increased healthcare spending. The aging population in Portugal has also contributed to the growth of the Multiple Sclerosis Drugs market, as the disease is more prevalent in older individuals. Additionally, Portugal has a high incidence of multiple sclerosis compared to other European countries, which has led to a greater demand for disease-modifying therapies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.